PLOS One · 19 Nov 2026
Efficacy and safety of hepatic arterial infusion chemotherapy combined with palliative transarterial chemoembolization followed by targeted therapy and immunotherapy in patients with BCLC stage C hepatocellular carcinoma: Clinical trial protocol
Yang Fang, Songnan Zhangh-index 1
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- OpenAlex0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background Interventional therapy combined with systemic treatment has demonstrated promising antitumor activity and an overall manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma (HCC). However, prospective evidence supporting the optimal combination strategy remains limited, and the tumor immune microenvironment (TIME) characteristics underlying differential treatment responses have not been systematically elucidated. The present study aims to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with palliative transarterial chemoembolization (TACE), followed by sequential targeted-immunotherapy, in treatment-naïve patients with BCLC stage C HCC, while also exploring the TIME features associated with therapeutic response. Methods This study is a prospective, single-arm, phase II clinical trial that will enroll treatment-naïve patients with BCLC C HCC who are unsuitable for surgical resection. Tumor tissue and peripheral blood samples will be collected at baseline prior to treatment initiation. All patients will receive HAIC with a modified FOLFOX regimen combined with palliative TACE. Immediately after the interventional procedure, patients will undergo intra-arterial infusion of bevacizumab (200–300 mg) and intravenous administration of sintilimab (200 mg) every three weeks for a total of six cycles. After two treatment cycles, patients will be stratified according to their treatment response, and five additional tumor tissue and blood samples will be collected from each group. Upon completion of local therapy, patients will continue with maintenance therapy consisting of intravenous bevacizumab (15 mg/kg) and sintilimab (200 mg) every three weeks until disease progression or the development of intolerable toxicity. Discussion This study will evaluate the efficacy and safety of HAIC combined with palliative TACE followed by sequential targeted-immunotherapy and explore TIME features associated with treatment response. The findings may provide evidence to inform multimodal treatment strategies and personalized therapy for advanced HCC. Trial registration number ChiCTR2500115704
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Songnan Zhang has the highest h-index among the authors (1).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (34)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 14 more references
A free account opens the rest of the citing papers and references on every paper’s page.